Speaker
Ingrid Maes
Presentation title
The Strategic Plan to Promote Clinical Trials in Belgium
Presentation outline
Belgium is an important country for the conduct of clinical trials. However, this position is challenged from many sides and far from self-evident. In order to build a sustainable clinical trials environment in Belgium, we need to understand the economic footprint of Belgium within the international clinical trials context. For The Initiative (ACRP, BAPU, BeAPP, FAGG and pharma.be), PwC gathered the insights and perspectives of key stakeholders in order to chart and assess the current situation and formulate clear, actionable recommendations on how a sustainable clinical trial environment in Belgium might be created.
Job title
Director Strategy & Operations Pharma & Healthcare - PwC Belgium
Biography
She has 23 years sector experience and has advised companies worldwide in strategy development, management decision support and innovation management.
Ingrid leads the Pharma & Healthcare consulting team in Belgium. She has a long-track of experience working with various life science companies in the US, Europe, and Asia, spanning the value chain — from R&D to supply chain and manufacturing, up to sales and marketing. She has led numerous projects, lectured and wrote on groundbreaking technologies and business models, and participated in various think tanks around the world, and advised regulators and trained them as well.
She has been in business development, innovation management, new product and service development, and market introduction roles at various international companies active in the pharmaceutical and life science sector. She has a Masters degree in Chemical & Life Science Engineering (University of Brussels, 1989), Psychology & pedagogic Master after master (University of Brussels, 1989) and has been on various international management positions throughout her career.
Her project work has focused largely in R&D, Manufacturing and sales & marketing. This included:
- Strategy development (growth, profitability strategy development)
- Management decision support and option analysis
- Scenario planning and foresight – future preparedness
- Go-to-market strategy development and implementation support
- Commercial and operational due diligence
- Operational improvement: cost reduction and performance improvement
- Technology management and selection
List of publications
Mergers & acquisitions surges, companion diagnostics accelerate New trends in the diagnostics market, such as personalised medicine, pay for performance, emphasis on prevention, translational research, … offer new opportunities for diagnostic players, such as companion diagnostics…
Take down the barriers to new growth This report highlights some of the misconceptions surrounding innovation and looks at how successful innovators create the right processes, structures and culture to move viable ideas through to implementation.
The race for global leadership The report is a multifaceted assessment of the capacity of countries to adapt to the changing nature of innovation. While there has been much anecdotal evidence involving the shift of innovation away from the US to new locals around the world, PwC analyzed and quantified the specific factors that contribute to medical technology innovation. The nine nations evaluated are Brazil, China, France, Germany, India, Israel, Japan, the United Kingdom and the U.S.
How universities manage innovation through disciplined and novel measure This report provides insight into successfully measuring innovation in academic medical centers and universities as well as the leading practices in technology transfer and commercialization. The information detailed in this report can be applied to help these institutions, as well as innovative corporations in other sectors, to successfully manage the innovation process.
Translating the promise into practice Personalised medicine is redefining the health industry, a.o.: advances in genomics and proteomics and related informatics capabilities and open innovation approaches , resulting in many partnerships.
Which path will you take? There will be a seismic shift in the R&D process, a.o.: Greater use of new technologies to ‘virtualise’ R&D; In-life testing and live licensing, in collaboration with regulators, healthcare providers, academia etc.
Which path will you take? Healthcare will shift in focus from treatment to prevention and the industry will polarise: mass market vs. specialty / niche. Pharmaceutical companies in 2020 will provide total healthcare packages.
Which path will you take? A 2020 world will enable Pharma to shape markets and focus on things that allow them to call the shots. To adapt, companies will need to acquire new skills and reorganise now.
Which path will you take? Create alignment with the healthcare value chain to deliver truly innovative drugs; invest in developing medicines the market wants to buy; create a web of alliances to offer supporting services.
The customisation of diagnosis, care and cure The 2020 health system will customise diagnosis, care and cure. Drivers for change can be identified, e.g. digitisation, increased consumerism… Patients will have many more access points to obtain information and care.
Publications on Clinical Trials
In March 2011 PwC developed an overview of the clinical trial situation in Belgium over the last five years, for pharma.be based on data extracted from the FAGG database.
In collaboration with the Dutch government and industry organisations, we performed a benchmark on the performance of clinical drug trials in the Netherlands in 2010. This was based on publication and citation success figures and a topline assessment of barriers and drivers.
This report by PwC investigates the impact of 4 different policy scenarios on the clinical trial situation in Poland :
- Status Quo;
- Additional incentives;
- Admin improvements;
- Restrictive legislation.
The relentless challenges of R&D productivity demand that companies further maximise value from R&D outsourcing. This research study on R&D outsourcing in hi-tech industries aims to chart the best practices and learnings across industries. A particular focus within the study will be on clinical outsourcing in pharmaceuticals.
